ArticleBMC infectious diseases2025
Time against tissue: case reports of fungal necrotizing fasciitis and the cost of delayed aggressive interventions.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNecrotizing fasciitis is a rare disease that causes the necrosis of subcutaneous tissues and muscle fascia in patients, and if not diagnosed and treated in due time may lead to the extreme morbidity and even death, with the mortality rate ranging from 6 to 33%. Fungal necrotizing fasciitis is even more rare and life threatening because of aggressive infection and less response to medical treatment. Literature has reported three times higher mortality rate in patients, who had positive fungal cultures and requiring multiple surgical detriments. CASE PRESENTATIONS: We are reporting cases of patients who were diagnosed and managed with fungal necrotizing fasciitis in a tertiary care hospital. CASE 1: A 45-year-old farmer with a non-healing abdominal wound later diagnosed with fungal necrotizing fasciitis, which improved after surgical debridement and anti-fungal treatment. The patient recovered after follow-up treatments. CASE 2: A 74-year-old diabetic man developed a groin wound that progressed to necrotizing fasciitis. Despite treatment, fungal cultures revealed growth of Candida tropicalis, Apophysomyces elegans, and Rhizopus species. The patient’s condition deteriorated and he passed away after the family opted for comfort care. CASE 3: A 54-year-old diabetic male involved in a road traffic accident developed sepsis and necrotizing fasciitis. Despite treatment and support the patient succumbed to his condition.
conclusionFungal necrotizing fasciitis, particularly in immunocompromised patients, is associated with high morbidity and mortality due to delayed recognition and treatment. Early surgical debridement along with empirical antifungal therapy should be considered standard practice. The report emphasizes the importance of early fungal cultures and timely, aggressive treatment to reduce complications and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.